This includes a potential immunomodulatory strategy to target NLRP3, Foxp3 and IRF4/8 in immune cells to achieve anti-inflammatory effects in IHD, although little data on concrete approaches is available yet. The gene discussed is IRF4; the disease is myocardial ischemia.